Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Part of paid clinical trials in Palo Alto, California.

Sponsor
William Shomali
Study ID
NCT03801434
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • BCR-JAK2 Fusion Protein Expression
  • Blasts 20 Percent or Less of Peripheral Blood White Cells
  • Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
  • Blasts More Than 5 Percent of Peripheral Blood White Cells
  • Blasts Under 20 Percent of Bone Marrow Nucleated Cells
  • Chronic Eosinophilic Leukemia, Not Otherwise Specified
  • Eosinophilia
  • Hepatomegaly
  • Hypereosinophilic Syndrome
  • JAK2 Gene Mutation
  • Splenomegaly
  • TEL-JAK2 Fusion Protein Expression

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.

Key Dates

Start date
Nov 15, 2019
Status verified
Dec 2025
Primary completion
Dec 30, 2028
Completion
Dec 30, 2028

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (ruxolitinib)
    Patients receive ruxolitinib PO BID on days 1-28. Treatment repeats for up to 6 cycles (28 days each) in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Overall response rate (ORR) [ Time Frame: 3 years ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Stanford Cancer Institute Palo AltoPalo AltoCalifornia94304
William E Shomali
[email protected]
650-498-6000
William E Shomali (PRINCIPAL_INVESTIGATOR)
OHSU Knight Cancer InstitutePortlandOregon97201-
University of UtahSalt Lake CityUtah84112-
Fred Hutchinson cancer research centerSeattleWashington98109-

Find similar trials in Palo Alto, CA

By research site
Stanford Cancer Institute Palo Alto· Palo Alto, CAOHSU Knight Cancer Institute· Portland, ORUniversity of Utah· Salt Lake City, UTFred Hutchinson cancer research center· Seattle, WA

Related Studies